AVR 2.32% $12.20 anteris technologies ltd

30cents today :), page-53

  1. 1,125 Posts.
    lightbulb Created with Sketch. 59
    Agree Hoods. The vax results being released is hotly anticipatead.We have been told a number of potential dates for the 'news' - what ever than may be, which have all passed. As I see it (and I do need glasses so my vision is not as clear as it could be), it is not so much the 'questionable results' delaying the results but, more likely, the results are not ready for release yet.

    We were told when m'ment thought they would be available (end of the year, early in the next q, middle of the next q etc), but that is not how it has panned out. Clinical research is somewhat unpredictable. Multiple reasons to delay progress, but doesn't mean it should be interpreted as doom and gloom.

    The message from the new chairman of the board suggested the time frame for results should be released soon. If nothing else, it will be half an idea as to when we can expect the results - which is more future prediction about this that we have seemed to have received before (like him already).

    Just my two cents worth..... ( and I hope the 20 and 30 c paddocks stay locked - I've invested just this side of the 40c gate today hoping that this is as far as it will go).

    When we hit 400+ centres (maybe xmas 2016) CC sales should cover staff costs......Pouring $ in to the vax will have reduced significantly (pending the right partnership deal) and the books will balance a lot easier. June - Dec 2017, results from aortic valve repairs and vascular repairs studies should be available to confirm the medical media process currently singing the praises of CC for valve repairs (Cardiothoracic and valve meetings seem to be featuring CC and valve repairs at the moment). Continual conservative growth of centres + increased uses and interest from consumers could easily have the 'shed' at full capacity. If so, a company with an annual revenue of $150 million and 180 million shares to me calculates to be gross revenue per share at about 83c. In two or three years, this will seem ridiculously cheap at 40ish cents.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.